Nucleate Podcast

Here's a segment breakdown with timestamps:
[0:58 – 1:43] Introduction & Career Background
[1:44 – 7:04] Regulation & the "Daughter Test"
[7:05 – 13:15] From Tech to Biotech: The Pivot
[13:16 – 21:35] AI at Retro & the OpenAI Partnership
[21:36 – 25:20] The 10-Year Lifespan Mission Explained
[25:21 – 33:20] Lead Program: Alzheimer's & Autophagy
[33:21 – 40:00] Broader Pipeline & Company Philosophy
[40:01 – 45:50] Cell Replacement vs. Cell Rejuvenation
[45:51 – 51:55] AI-Designed Transcription Factors & Partial Reprogramming
[51:56 – 54:03] On Biohackers & the DTC Longevity Industry
[54:04 – 56:02] "Whose Lives Are We Extending?" & Closing Thoughts

See the episode breakdown with time stamps below:
0:00 – Cold open: the "unexpected collaboration" teaser
0:35 – Growing up in Zimbabwe and an unplanned path into medicine
5:41 – The "9-month detour" into pharma that turned into a 30-year career
20:01 – Learning to lead: finance, business instincts, and the power of asking questions
23:55 – Launching Gleevec — and the patients who make it all worth it
31:21 – Taking the leap: becoming CEO of Millennium and betting big on Velcade
39:41 – Layoffs done right: dignity, trust, and the "milk mustache" story
49:57 – Inside the $8.8B Takeda acquisition and navigating a clash of cultures
1:08:30 – Failure and resilience: Forum Therapeutics and a rocky start at Lundbeck
1:22:48 – The $2.2B Alder bet, boardroom battles over share classes, and closing lessons on culture (plus the rapid-fire round)

Time Stamps:
(3:10) Phillip’s background and how it shaped his character
(6:13) What first sparked his passion for science
(9:15) What inspired his PhD journey
(17:35) The discovery of restriction enzymes and DNA synthesis, concerns about DNA manipulation and how NIH guidelines came to be
(25:00) How to communicate your science and translate that knowledge for public benefit
(33:17 The discovery of RNA splicing
(48:40) The founding of Alnylam
(58:10) The creation of the biotech industry
(1:03:30) How to keep up with the latest science and important trends to watch
(1:12:55) Advice for founders looking to launch their own companies
(1:16:47) Traits to look for in a mentor and what makes a strong mentor-mentee relationship
(1:19:53) Critical pieces of company culture that drive success
(1:24:59) Quick fire questions

Here is a segment breakdown of the episode:
0:00–1:42 — Intro and guest background: host frames the episode and introduces Nolan Townsend's career across Wall Street, Pfizer, and Lexeo.
1:42–3:21 — From finance to healthcare: what drew Nolan into life sciences and the appeal of the industry's complexity.
3:21–10:13 — Pfizer's international roles: P&L leadership in Korea, Ukraine, and beyond, and how working across health systems and cultures shaped him.
10:14–19:00 — Rare disease leadership at Pfizer: the tafamidis/TTR amyloid cardiomyopathy story and its influence on Lexeo's founding thesis.
19:00–24:16 — Founding Lexeo in January 2020: the decision to leave Pfizer, launching amid COVID, and building a team remotely.
24:19–37:39 — Lexeo's scientific thesis: applying oncology's precision-medicine model to cardiac disease, the lead pipeline (Friedreich's ataxia, arrhythmogenic cardiomyopathy), and the Alzheimer's/APOE program and why it was deprioritized.
37:39–47:20 — Fundraising strategy: de-risking the story, the cooled IPO market, tranche financing, and advice for founders raising seed/Series A rounds.
47:20–50:00 — Mentors: Ron Crystal, Steve Altschuler, Ted Love, and the lessons drawn from each.
50:23–56:04 — Rapid-fire questions: influential book (Clayton Christensen), views on what's holding back broader use of gene therapy, and the most underrated CEO skill.
56:04–57:33 — Closing question (life outside biotech) and sign-off.

Time Stamps:
0:45 Introduction to Dana Aftab and what sparked his passion for science
6:39 His Ph.D. experience at Yale that led to a breakthrough in compound screening
16:15 Why that soured him on biotech and what ultimately drew him back in
24:33 Navigating the transition into industry by trusting his gut
30:09 The Exelixis-MetaXen acquisition
37:18 Taking the lead as a helping guide to younger scientist
41:00 What does it take to be a good manager
48:45 Discovery and development of CABOMETYX® (cabozantinib)
57:15 How differentiating clinical data changed the trajectory of Exelixis
1:00:34 Navigating the restructuring process
1:07:13 Rebuilding the Exelixis team
1:11:26 His return to science
1:13:30 Advice for founders on what makes a strong potential partner
1:20:07 Quick fire questions